Efficacy of pulmonary surfactant with budesonide in premature infants: A systematic review and meta-analysis.

Pulmonary surfactant (PS) is one of the main treatment for neonates with respiratory distress syndrome (RDS). Budesonide has recently been studied as an additional treatment in such cases, but there is limited evidence supporting this. This study was implemented to determine the efficacy of PS combi...

Full description

Saved in:
Bibliographic Details
Main Authors: Nanthida Phattraprayoon, Bing Tan, Mingkwan Na Takuathung
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0312561
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841533206393782272
author Nanthida Phattraprayoon
Bing Tan
Mingkwan Na Takuathung
author_facet Nanthida Phattraprayoon
Bing Tan
Mingkwan Na Takuathung
author_sort Nanthida Phattraprayoon
collection DOAJ
description Pulmonary surfactant (PS) is one of the main treatment for neonates with respiratory distress syndrome (RDS). Budesonide has recently been studied as an additional treatment in such cases, but there is limited evidence supporting this. This study was implemented to determine the efficacy of PS combined with budesonide in premature infants. To achieve this, we conducted a systematic review and meta-analysis of randomized controlled trials by searching PubMed, Scopus, Embase, and the Cochrane Library from inception until July 12, 2024. We utilized a random-effects model to calculate the risk ratio and mean differences (MDs) with 95% confidence intervals (CIs) for the clinical outcomes of PS with budesonide versus PS alone. We used the GRADE approach to assess the quality of the evidence. We included 26 randomized controlled trials with a total of 2701 patients in the analysis. Treatments of PS with budesonide and PS alone were compared in all trials. PS with budesonide reduced bronchopulmonary dysplasia (BPD) incidence (risk ratio, 0.61; 95% CI, 0.51, 0.73), duration of mechanical or invasive mechanical ventilation (MD, -2.21 days; 95% CI, -2.72, -1.71), duration requiring oxygen (MD, -5.86 days; 95% CI, -8.44, -3.29), and hospitalization time (MD, -5.61 days; 95% CI, -8.65, -2.56). These results were based on low to very low evidence certainty. Only moderate-to-severe BPD or severe BPD showed a significant reduction when PS was used in conjunction with budesonide, a finding supported by moderate evidence certainty. Our study showed that the administration of PS with budesonide significantly improved respiratory outcomes, including the incidence of BPD, duration of mechanical or invasive mechanical ventilation, duration requiring oxygen, and hospitalization time in preterm infants, without short-term adverse drug events. However, the evidence certainty was mostly low to very low.
format Article
id doaj-art-fbf37b498a66457bbd6843e637e55359
institution Kabale University
issn 1932-6203
language English
publishDate 2025-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-fbf37b498a66457bbd6843e637e553592025-01-17T05:31:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01201e031256110.1371/journal.pone.0312561Efficacy of pulmonary surfactant with budesonide in premature infants: A systematic review and meta-analysis.Nanthida PhattraprayoonBing TanMingkwan Na TakuathungPulmonary surfactant (PS) is one of the main treatment for neonates with respiratory distress syndrome (RDS). Budesonide has recently been studied as an additional treatment in such cases, but there is limited evidence supporting this. This study was implemented to determine the efficacy of PS combined with budesonide in premature infants. To achieve this, we conducted a systematic review and meta-analysis of randomized controlled trials by searching PubMed, Scopus, Embase, and the Cochrane Library from inception until July 12, 2024. We utilized a random-effects model to calculate the risk ratio and mean differences (MDs) with 95% confidence intervals (CIs) for the clinical outcomes of PS with budesonide versus PS alone. We used the GRADE approach to assess the quality of the evidence. We included 26 randomized controlled trials with a total of 2701 patients in the analysis. Treatments of PS with budesonide and PS alone were compared in all trials. PS with budesonide reduced bronchopulmonary dysplasia (BPD) incidence (risk ratio, 0.61; 95% CI, 0.51, 0.73), duration of mechanical or invasive mechanical ventilation (MD, -2.21 days; 95% CI, -2.72, -1.71), duration requiring oxygen (MD, -5.86 days; 95% CI, -8.44, -3.29), and hospitalization time (MD, -5.61 days; 95% CI, -8.65, -2.56). These results were based on low to very low evidence certainty. Only moderate-to-severe BPD or severe BPD showed a significant reduction when PS was used in conjunction with budesonide, a finding supported by moderate evidence certainty. Our study showed that the administration of PS with budesonide significantly improved respiratory outcomes, including the incidence of BPD, duration of mechanical or invasive mechanical ventilation, duration requiring oxygen, and hospitalization time in preterm infants, without short-term adverse drug events. However, the evidence certainty was mostly low to very low.https://doi.org/10.1371/journal.pone.0312561
spellingShingle Nanthida Phattraprayoon
Bing Tan
Mingkwan Na Takuathung
Efficacy of pulmonary surfactant with budesonide in premature infants: A systematic review and meta-analysis.
PLoS ONE
title Efficacy of pulmonary surfactant with budesonide in premature infants: A systematic review and meta-analysis.
title_full Efficacy of pulmonary surfactant with budesonide in premature infants: A systematic review and meta-analysis.
title_fullStr Efficacy of pulmonary surfactant with budesonide in premature infants: A systematic review and meta-analysis.
title_full_unstemmed Efficacy of pulmonary surfactant with budesonide in premature infants: A systematic review and meta-analysis.
title_short Efficacy of pulmonary surfactant with budesonide in premature infants: A systematic review and meta-analysis.
title_sort efficacy of pulmonary surfactant with budesonide in premature infants a systematic review and meta analysis
url https://doi.org/10.1371/journal.pone.0312561
work_keys_str_mv AT nanthidaphattraprayoon efficacyofpulmonarysurfactantwithbudesonideinprematureinfantsasystematicreviewandmetaanalysis
AT bingtan efficacyofpulmonarysurfactantwithbudesonideinprematureinfantsasystematicreviewandmetaanalysis
AT mingkwannatakuathung efficacyofpulmonarysurfactantwithbudesonideinprematureinfantsasystematicreviewandmetaanalysis